Related Articles
Effect of PTEN loss on metabolic reprogramming in prostate cancer cells
HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain Corrigendum in /10.3892/mmr.2022.12746
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro
Gas chromatography‑time of flight/mass spectrometry‑based metabonomics of changes in the urinary metabolic profile in osteoarthritic rats
Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis